RUNX1 and acute myeloid leukemia: C/EBPα expression or activity is commonly diminished in acute myeloid leukemia (AML) cases, with CEBPA open reading frame point mutations impacting trans-activation or DNA-binding, RUNX1-ETO reducing CEBPA transcription, and other alterations such as those leading to Trib2 over-expression potentially also impeding C/EBPα expression, and thereby myeloid differentiation, to contribute to myeloid transformation [7–9].